JPWO2020074894A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020074894A5 JPWO2020074894A5 JP2021517866A JP2021517866A JPWO2020074894A5 JP WO2020074894 A5 JPWO2020074894 A5 JP WO2020074894A5 JP 2021517866 A JP2021517866 A JP 2021517866A JP 2021517866 A JP2021517866 A JP 2021517866A JP WO2020074894 A5 JPWO2020074894 A5 JP WO2020074894A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- use according
- weight
- rpl554
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 239000002245 particle Substances 0.000 claims 9
- CSOBIBXVIYAXFM-BYNJWEBRSA-N ensifentrine Chemical compound c-12cc(OC)c(OC)cc2CCn(c(n2CCNC(N)=O)=O)c-1c\c2=N/c1c(C)cc(C)cc1C CSOBIBXVIYAXFM-BYNJWEBRSA-N 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 6
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical group FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940071648 metered dose inhaler Drugs 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- PVKCAQKXTLCSBC-UHFFFAOYSA-N 1h-isoquinolin-4-one Chemical compound C1=CC=C2C(=O)C=NCC2=C1 PVKCAQKXTLCSBC-UHFFFAOYSA-N 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024091837A JP7836853B2 (ja) | 2018-10-09 | 2024-06-05 | Ｈｆａ－１３４ａ中のｒｐｌ５５４を含む吸入による投与用医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816447.5 | 2018-10-09 | ||
| GB1816447.5A GB2578093B (en) | 2018-10-09 | 2018-10-09 | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| PCT/GB2019/052863 WO2020074894A1 (en) | 2018-10-09 | 2019-10-09 | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091837A Division JP7836853B2 (ja) | 2018-10-09 | 2024-06-05 | Ｈｆａ－１３４ａ中のｒｐｌ５５４を含む吸入による投与用医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513566A JP2022513566A (ja) | 2022-02-09 |
| JPWO2020074894A5 true JPWO2020074894A5 (enExample) | 2022-10-11 |
| JP7578587B2 JP7578587B2 (ja) | 2024-11-06 |
Family
ID=64394831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517866A Active JP7578587B2 (ja) | 2018-10-09 | 2019-10-09 | Ｈｆａ－１３４ａ中のｒｐｌ５５４を含む吸入による投与用医薬組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20210379053A1 (enExample) |
| EP (2) | EP3960157A1 (enExample) |
| JP (1) | JP7578587B2 (enExample) |
| KR (1) | KR20210073532A (enExample) |
| CN (1) | CN112912064B (enExample) |
| AU (1) | AU2019358585B2 (enExample) |
| BR (1) | BR112021006712A2 (enExample) |
| CA (1) | CA3113167A1 (enExample) |
| CY (1) | CY1124943T1 (enExample) |
| DK (1) | DK3820446T3 (enExample) |
| ES (1) | ES2899744T3 (enExample) |
| GB (1) | GB2578093B (enExample) |
| HR (1) | HRP20220053T1 (enExample) |
| HU (1) | HUE057780T2 (enExample) |
| IL (1) | IL282032B1 (enExample) |
| LT (1) | LT3820446T (enExample) |
| MX (2) | MX2021003599A (enExample) |
| MY (1) | MY207302A (enExample) |
| PH (1) | PH12021550767A1 (enExample) |
| PL (1) | PL3820446T3 (enExample) |
| PT (1) | PT3820446T (enExample) |
| RS (1) | RS62775B1 (enExample) |
| SG (1) | SG11202102567UA (enExample) |
| SI (1) | SI3820446T1 (enExample) |
| SM (1) | SMT202200044T1 (enExample) |
| WO (1) | WO2020074894A1 (enExample) |
| ZA (1) | ZA202102039B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3142701T1 (en) | 2014-05-12 | 2018-08-31 | Verona Pharma Plc | NEW TREATMENT |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB2594480A (en) * | 2020-04-28 | 2021-11-03 | Verona Pharma Plc | New treatment |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| EP4609864A4 (en) * | 2022-10-28 | 2026-02-18 | Jiangsu Hengrui Pharmaceuticals Co Ltd | PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| TW202506117A (zh) | 2023-06-26 | 2025-02-16 | 英商維羅納製藥Ｐｌｃ公司 | 顆粒組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100415743C (zh) | 1999-03-31 | 2008-09-03 | 韦尔纳利斯有限公司 | 嘧啶并[6,1-a] 异喹啉-4-酮衍生物 |
| AR082601A1 (es) * | 2010-08-09 | 2012-12-19 | Verona Pharma Plc | Formas cristalinas de compuestos de pirimido[6,1-a]isoquinolin-4-ona |
| KR20200015828A (ko) * | 2012-02-28 | 2020-02-12 | 아이슈티카 홀딩스 인코포레이티드. | 흡입용 약제학적 조성물 |
| US9700558B2 (en) * | 2013-03-15 | 2017-07-11 | Verona Pharma Plc | Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist |
| SI3142701T1 (en) * | 2014-05-12 | 2018-08-31 | Verona Pharma Plc | NEW TREATMENT |
| HUE055527T2 (hu) * | 2014-09-15 | 2021-12-28 | Verona Pharma Plc | RPL554-t tartalmazó folyékony inhalációs készítmény |
| GB201502260D0 (en) * | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
-
2018
- 2018-10-09 GB GB1816447.5A patent/GB2578093B/en active Active
-
2019
- 2019-10-09 LT LTEPPCT/GB2019/052863T patent/LT3820446T/lt unknown
- 2019-10-09 WO PCT/GB2019/052863 patent/WO2020074894A1/en not_active Ceased
- 2019-10-09 SI SI201930145T patent/SI3820446T1/sl unknown
- 2019-10-09 MY MYPI2021001479A patent/MY207302A/en unknown
- 2019-10-09 SG SG11202102567UA patent/SG11202102567UA/en unknown
- 2019-10-09 EP EP21198029.7A patent/EP3960157A1/en active Pending
- 2019-10-09 EP EP19790718.1A patent/EP3820446B1/en active Active
- 2019-10-09 JP JP2021517866A patent/JP7578587B2/ja active Active
- 2019-10-09 MX MX2021003599A patent/MX2021003599A/es unknown
- 2019-10-09 ES ES19790718T patent/ES2899744T3/es active Active
- 2019-10-09 CN CN201980065895.8A patent/CN112912064B/zh active Active
- 2019-10-09 RS RS20211599A patent/RS62775B1/sr unknown
- 2019-10-09 SM SM20220044T patent/SMT202200044T1/it unknown
- 2019-10-09 HU HUE19790718A patent/HUE057780T2/hu unknown
- 2019-10-09 PT PT197907181T patent/PT3820446T/pt unknown
- 2019-10-09 DK DK19790718.1T patent/DK3820446T3/da active
- 2019-10-09 BR BR112021006712-4A patent/BR112021006712A2/pt unknown
- 2019-10-09 KR KR1020217010706A patent/KR20210073532A/ko not_active Ceased
- 2019-10-09 PL PL19790718T patent/PL3820446T3/pl unknown
- 2019-10-09 CA CA3113167A patent/CA3113167A1/en active Pending
- 2019-10-09 HR HRP20220053TT patent/HRP20220053T1/hr unknown
- 2019-10-09 AU AU2019358585A patent/AU2019358585B2/en active Active
- 2019-10-09 US US17/280,452 patent/US20210379053A1/en not_active Abandoned
-
2021
- 2021-03-25 ZA ZA2021/02039A patent/ZA202102039B/en unknown
- 2021-03-26 MX MX2024001499A patent/MX2024001499A/es unknown
- 2021-04-04 IL IL282032A patent/IL282032B1/en unknown
- 2021-04-06 PH PH12021550767A patent/PH12021550767A1/en unknown
-
2022
- 2022-02-02 CY CY20221100086T patent/CY1124943T1/el unknown
-
2024
- 2024-03-26 US US18/616,878 patent/US20250049781A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211035T1 (hr) | Tekuća formulacija za inhalaciju koja sadrži rpl554 | |
| ES2266322T3 (es) | Nuevo uso de budesonida y formoterol. | |
| JP2017528479A5 (enExample) | ||
| KR20120015295A (ko) | 점막 내층의 생물물리학적 성질의 변경을 위한 구연산 칼슘 및 젖산 칼슘 제형 | |
| Pomázi et al. | Effect of polymers for aerolization properties of mannitol-based microcomposites containing meloxicam | |
| BRPI0707634A2 (pt) | alfa-1 antitripsina para tratar episàdios de exacerbaÇço de doenÇas pulmonares | |
| JP2019534270A5 (enExample) | ||
| AU2005316687B2 (en) | Compositions and methods for pulmonary conditions | |
| JP2009515941A (ja) | 医薬組成物 | |
| HRP20240288T1 (hr) | Tekući farmaceutski sastav koji sadrži ensifentrin i glikopirolat | |
| JPWO2020074894A5 (enExample) | ||
| HUP0303755A2 (hu) | Szalmeterol és flutikaszon-propionát kombináció alkalmazása és ezt tartalmazó gyógyszerkészítmény | |
| JPWO2021028679A5 (enExample) | ||
| FI4199922T3 (fi) | (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa | |
| JP2008502699A5 (enExample) | ||
| KR102637303B1 (ko) | 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법 | |
| WO2017101696A1 (zh) | 治疗急慢性呼吸困难的西药组合物及其制备方法 | |
| RU2021109697A (ru) | Фармацевтические композиции, содержащие RPL554 в HFA-134A для введения посредством ингаляции | |
| JPWO2019204583A5 (enExample) | ||
| JP2024113096A5 (enExample) | ||
| RU2022103508A (ru) | Фармацевтическая композиция, содержащая энсифентрин | |
| KR20240105510A (ko) | 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법 | |
| JP2023528883A (ja) | 呼吸器系傷害改善用医薬組成物及び呼吸器系傷害改善用医薬組成物の製造のための用途 | |
| NZ767296B2 (en) | Liquid Inhalation Formulation Comprising RPL554 | |
| JP2022552489A (ja) | 肺疾患のための吸入可能な乾燥粉末組成物 |